Exosomes
Exosomes (Extracellular Vesicles, EVs) Production |
||
Exosomes are nano-sized vesicles that enable unique intercellular communication by transferring DNAs, microRNAs, non-coding RNAs, and lipids.
Exosomes have been identified as having potential applications in diagnostics and therapeutics for various diseases.
Serving as vesicular carriers, exosomes can facilitate communication between cells, making them a central focus in therapeutic applications, encompassing cargo properties, targeting functions, and diverse tissue-specific sources. |
|
|
Our Capabilities:
|
||
The Flowchart for Exosome Production from MSCs Using 3D Microcarrier-Based Process: |
||
This flowchart outlines how Mycenax utilizes the 3D microcarrier-based process for the cultivation of mesenchymal stem cells (MSCs) and the purification of exosomes from the harvested supernatant, thereby producing the final exosome drug product. |
||
|
||
Leveraging Microcarrier-Based Process, Roosterbio’s Products and Ambr250 Mini-Bioreactor System to Increase Exosome Productivity
|
||
BMMSC source: RoosterBio
|
|
|
White paper: Tackling Cell and Gene Therapy Manufacturing Challenges (2023/12/20) |
||
Keyword: Cell therapy, Cell and Gene Therapy, Exosome, Extracellular Vesicles, EVs, Microcarrier, 3D process, MSC, CDMO, CMO, GMP manufacturing |
Exosomes (Extracellular Vesicles, EVs) Production |
||
Exosomes are nano-sized vesicles that enable unique intercellular communication by transferring DNAs, microRNAs, non-coding RNAs, and lipids.
Exosomes have been identified as having potential applications in diagnostics and therapeutics for various diseases.
Serving as vesicular carriers, exosomes can facilitate communication between cells, making them a central focus in therapeutic applications, encompassing cargo properties, targeting functions, and diverse tissue-specific sources. |
|
|
Our Capabilities:
|
||
The Flowchart for Exosome Production from MSCs Using 3D Microcarrier-Based Process: |
||
This flowchart outlines how Mycenax utilizes the 3D microcarrier-based process for the cultivation of mesenchymal stem cells (MSCs) and the purification of exosomes from the harvested supernatant, thereby producing the final exosome drug product. |
||
|
||
Leveraging Microcarrier-Based Process, Roosterbio’s Products and Ambr250 Mini-Bioreactor System to Increase Exosome Productivity |
||
BMMSC source: RoosterBio
|
|
|
White paper: Tackling Cell and Gene Therapy Manufacturing Challenges (2023/12/20) |
||
Keyword: Cell therapy, Cell and Gene Therapy, Exosome, Extracellular Vesicles, EVs, Microcarrier, 3D process, MSC, CDMO, CMO, GMP manufacturing |